
Deuruxolitinib ‘transforming lives’ in treatment of alopecia areata
March 20, 2023 1 min read Source/Disclosures Source: King B. Results from Thrive-Aa2: A double blind, placebo-controlled phase 3 clinical trial of deuruxolitinib (Ctp-543), an oral JAK inhibitor, In adult patients with moderate to severe alopecia …